Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma

Neoplasma

Volumn 58, Issue 6, 2011, Pages 499-506

  Scudla, V ^a   Petrova, P ^a   Minarik, J ^a   Pika, T ^a   Bacovsky, J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Biological markers; Clinical stages; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Osteopontin

Indexed keywords

ANGIOGENIN; BIOLOGICAL MARKER; ENDOSTATIN; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOCALCIN; OSTEOPONTIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; BLOOD; MIDDLE AGED; PARAPROTEINEMIA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROGNOSIS;

EID: 84856375223     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_06_499     Document Type: Article

References (43)

1. URASHIMA M, CHEN BP, CHEN S, PINKUS GS, BRONSON RT et al. The development of a model for the homing of BIOLOGICAL PARAMETERS IN MULTIPLE MYELOMA 505 multiple myeloma cells to human bone marrow. Blood 1997; 90: 754-765.
2. HIDESHIMA T, BERGSAGEL PL, KUEHL MW, ANDERSON KC. Advances in biology of multiple myeloma: Clin applications. Blood 2004; 104: 607-618. doi: 10.1182/blood-2004-01-0037
3. International Myeloma Working Group. Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749-757. doi:10.1046/j.1365-2141.2003.04355.x
4. BALAKUMARAN A, ROBEY PG, FEDARKO N, LANDGREN O. Expert Rev Molecular Diagnostics 2010; 10: 465-480. doi:10.1586/erm.10.31
5. SCUDLA V, BUDIKOVA M, PIKA T, BACOVSKY J, MINARIK J et al. The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma. Čas Lék Čes 2009; 148: 315-322 (In Czech).
6. SCUDLA V, PIKA T, BUDIKOVÁ M, PETROVA P, MINARIK J et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma 2010; 57: 102-110. doi: 10.4149/neo_2010_02_102
7. SCUDLA V, BUDIKOVA M, PETROVA P, MINARIK J, PIKA T et al. Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma. Klin Onkol 2010; 23: 171-181 (In Czech).
8. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854. doi:10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
9. GREIPP PR, SAN MIGUEL J, DURIE BGM, CROWLEY JJ, BARLOGIE B et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420. doi:10.1200/ JCO.2005.04.242
10. BATAILLE R, DELMAS PD, CHAPPARD D, SANY J. Abnormal serum bone GLA protein levels in multiple myeloma:crucial role of bone formation and prognostic implications. Cancer 1990; 66: 167-172. doi:10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9
11. BATAILLE R, CHAPPARD D, KLEIN B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 285-295.
12. GRAVALLESE EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003; 112: 147-149.
13. ERGÜN S, KILIC N, WURMBACK JH, EBRAHIMEJAD A, FERNANDO M et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001; 4: 193-206. doi:10.1023/A:1014027218980
14. LENTZSCH S, GRIES M, JANZ M, BARGOU R, DÖRKEN B et al. Macrophage inflammatory protein 1-α (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568-3573. doi:10.1182/blood-2002-08-2383
15. CHOI SJ, CRUZ JC, CRAIG F, CHUNG H, DEVLIN RD et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
16. TERPOS E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Reviews 2006; 32(s1): 15-19. doi:10.1016/S0305-7372(06)80004-6
17. RENZULLI MR, TERRAGNA C, TESTONI N, NICCI C, TACCIOLI C et al. Insulin-like growth factor 1 (IGF-1) is overexpressed in multiple myeloma plasma cells (PC) and regulates the expression of the IGF-1 receptor. Haematologica 2006;91:100-101.
18. MENU E, VAN VALCKENBORHG E, VAN CAMP B, VANDERKERKEN K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115: 49-57. doi:10.1080/13813450902736583
19. DHODAPKAR KM, BARBUTO S, MATTHEWS P, KUKREJA A, MAZUMDER A et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112: 2878-2885. doi:10.1182/blood-2008-03-143222
20. KYLE RA, RAJKUMAR SV. Monoclonal gammopathies of undetermined significance and smouldering multiple myeloma: emphasis on risk factor for progression. Brit J Haematol 2007; 139: 730-743. doi:10.1111/j.1365-2141.2007.06873.x
21. VACCA A, RIA R, RIBATTI D, SEMERARO F, DJONOV V et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176-185.
22. POUR L, HAJEK R, BUCHLER T, MAISNAR V, SMOLEJ L. Angiogenesis and antiangiogenic therapy in neoplasias. Vnitř Lék 2004; 50: 930-938 (In Czech).
23. KYLE RA, DURIE BGM, RAJKUMAR SV, LANDGREN O, BLADE J et al, International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma): IMWG consensus perspective risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127. doi:10.1038/leu.2010.60
24. PAIVA B, ALMEINA J, PREREZ-ANDRES M, MATEO G, POLEZ A. et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry Part B, Clin Cytometry 2010; 78: 239-252.
25. HAJEK R, ADAM Z, MAISNAR V, BALLOVA V, KESSLER P et al. Guidelines of the Czech myeloma group. Diagnosis and therapy of multiple myeloma. Transfuze Hematol dnes 2009; 15 (s2): 1-80 (In Czech).
26. CORSO A, ARCAINI L, MANGIACAVALLI S, ASTORI C, ORLANDI E et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001; 86: 394-398.
27. FONSECA R, TRENDLE MC, LEONG T, KYLE RA, OKEN M et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Brit J Haematol 2000; 109: 24-29. doi:10.1046/j.1365-2141.2000.01960.x
28. LAROCHE M, ATTAL M, DROMER C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheum 1996; 15: 347-352 doi:10.1007/BF02230356
29. ALEXANDRAKIS MG, PASSAM FH, MALLIARAKI N, KATACHANAKIS C, KYRIAKOU DS, MARGIORIS AN. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002; 325: 51-57. doi:10.1016/S0009-8981(02)00246-2
30. ABILDGAARD N, BENTZEN SM, NIELSEN JL, for the Nordic Myeloma Study Group (NMSG). Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Brit J Haematol 1997; 96: 103-110. doi:10.1046/j.1365- 2141.1997.8672495.x
31. WOITGE HW, HORN E, KECK AV, AULER B, SEIBEL MJ, PECHERSTORFER M. Biochemical markers of bone formation in patients with plasma cell dyscracias and benign osteoporosis. Clin Chem 2001; 47: 686-693.
32. HEIDER V, FLEISSNER C, ZAVRSKI I, KAISER M, HECHT M et al. Bone markers in multiple myeloma. Eur J Cancer 2006; 42: 1544-1553. doi:10.1016/j.ejca.2005.11.034
33. ROBBIANI DF, COLON K, ELY S, ELY S, CHESI M, BERGSAGEL PL. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 2007; 25: 16-20. doi:10.1002/hon.803
34. JOHNSTON NI, GUNASEKHARAN VK, RAVINDRANATH A, O'CONNELL C, JOHNSTON PG, EL-TANANI MK. Osteopontin as a target for cancer therapy. Frontiers in Bioscience 2008; 13: 4361-4372. doi:10.2741/3009
35. STIFTER S, VALKOVIC T, NACINOVIC-DULETIC A, MATUS AN-ILIJAS M et al. Vascular endothelial growth factor, osteopontin and NF-κB/P65 expression in multiple myeloma. Haematologica 2008; 93(s1): 80.
36. SAEKI Y, MIMA T, ISHII T, OGATA A, KOBAYASHI H et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Brit J Haematol 2003; 123: 263-270. doi:10.1046/j.1365-2141.2003.04589.x
37. STANDAL T, HJORTH-HANSEN H, RASMUSSEN T, DAHL IM, LENHOFF S et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89: 174-182.
38. RAJKUMAR SV. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
39. POUR L, SVACHOVA H, ADAM Z, MIKULKOVA Z, BURESOVA L et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010; 57: 29-34. doi:10.4149/neo_2010_01_029
40. TERPOS E, POLITOU M, SZYDLO R, GOLDMAN JM, APPERLEY JF et al. Serum levels of macrophage inflammatory protein-1 α (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106-109. doi:10.1046/j.1365- 2141.2003.04561.x
41. ABE M, HIURA K, WILDE J, MORIYAMA K, HASHIMOTO T et al. Role for macrophage inflammatory protein MIP-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195-2202.
42. TERPOS E, TASIDOU A, ROUSSOU M, KASTRITIS E, MIGKOU M et al. Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with advanced myeloma, extensive bone disease and elevated microvessel density in newly diagnosed patients with multiple myeloma. Haematologica 2009; 94: 146.
43. GRECO C, VITELLI G, VERCILLO G, VONA R, GIANNARELLI D et al. Reduction of serum IGF-1 levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and κ-ras gene mutation. J Exp Clin Cancer Res